Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Market Capitalization on June 03, 2024: USD 243.38 M

Monte Rosa Therapeutics Inc Market Capitalization is USD 243.38 M on June 03, 2024, a -33.91% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Monte Rosa Therapeutics Inc 52-week high Market Capitalization is USD 424.30 M on March 25, 2024, which is 74.34% above the current Market Capitalization.
Monte Rosa Therapeutics Inc 52-week low Market Capitalization is USD 301.92 K on March 11, 2024, which is -99.88% below the current Market Capitalization.
Monte Rosa Therapeutics Inc average Market Capitalization for the last 52 weeks is USD 278.18 M.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends